IL316096A - Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate - Google Patents

Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Info

Publication number
IL316096A
IL316096A IL316096A IL31609624A IL316096A IL 316096 A IL316096 A IL 316096A IL 316096 A IL316096 A IL 316096A IL 31609624 A IL31609624 A IL 31609624A IL 316096 A IL316096 A IL 316096A
Authority
IL
Israel
Prior art keywords
difluoropropan
fluoropropyl
azetidin
pyrido
indol
Prior art date
Application number
IL316096A
Other languages
English (en)
Hebrew (he)
Inventor
Hao Hou
Laura Jerke
Michael Kammerer
Original Assignee
Hoffmann La Roche
Genentech Inc
Hao Hou
Laura Jerke
Michael Kammerer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc, Hao Hou, Laura Jerke, Michael Kammerer filed Critical Hoffmann La Roche
Publication of IL316096A publication Critical patent/IL316096A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL316096A 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate IL316096A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22170407 2022-04-28
PCT/EP2023/061060 WO2023209062A1 (en) 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Publications (1)

Publication Number Publication Date
IL316096A true IL316096A (en) 2024-12-01

Family

ID=81392840

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316096A IL316096A (en) 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3 ,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Country Status (11)

Country Link
US (1) US20250282775A1 (enExample)
EP (1) EP4514792A1 (enExample)
JP (1) JP2025512583A (enExample)
KR (1) KR20250006222A (enExample)
CN (1) CN119156386A (enExample)
AU (1) AU2023262166A1 (enExample)
CA (1) CA3255956A1 (enExample)
IL (1) IL316096A (enExample)
MX (1) MX2024013116A (enExample)
TW (1) TW202400141A (enExample)
WO (1) WO2023209062A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219830A1 (en) * 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
TWI915239B (zh) 2018-06-21 2026-02-11 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法

Also Published As

Publication number Publication date
AU2023262166A1 (en) 2024-10-17
CN119156386A (zh) 2024-12-17
TW202400141A (zh) 2024-01-01
MX2024013116A (es) 2024-11-08
WO2023209062A1 (en) 2023-11-02
EP4514792A1 (en) 2025-03-05
JP2025512583A (ja) 2025-04-17
US20250282775A1 (en) 2025-09-11
CA3255956A1 (en) 2023-11-02
KR20250006222A (ko) 2025-01-10

Similar Documents

Publication Publication Date Title
IL278063A (en) Solid forms of 3-((R3,R1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4 3,1-tetrahydro-H2-pyrido[4,3-B]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
AU2003256953A8 (en) System for mobil broadband networking using dynamic quality of service provisioning
ZA200709587B (en) Signaling quality of service (QOS) parameters for a multimedia session
CN1413192A (zh) 取代的吲哚曼尼希碱
PL1612203T3 (pl) Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
IL196626A (en) Preparation of 3 - [(r1, r2–3– (dimethylamino) –1 – ethyl – 2 – methylpropyl] phenol
IL196627A (en) Preparation of (r2, r3) –3– (3– methoxyphenyl) - n, n, 2– trimethylphentanamine
IL178185A0 (en) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
HUE072069T2 (hu) 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
NZ597433A (en) 3-phenoxymethylpyrrolidine compounds
CL2008003358A1 (es) Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.
MX2024013116A (es) Forma solida de tartrato 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol
BRPI0806411B8 (pt) processo para a preparação de um composto e compostos
WO2007047972A3 (en) Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
JP2025525370A5 (enExample)
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
IL196808A0 (en) Polymorph of (r)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-s-ylcarbamoyl-methyl)-1-azoni a-bicyclo-[2.2.2] octane bromide
CA3310705A1 (en) Quality of experience metrics, reporting and configuration for real-time media communication services
ZA200608134B (en) 1-(1H-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (NE) and the serotonine (5-HT) activity and the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
MA52973A (fr) Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisation
JP2005516994A5 (enExample)
US20120220665A1 (en) Inhibiting Neurotransmitter Reuptake
CA3272837A1 (en) Quality of service flow model for low-latency services
ECSP077332A (es) Nuevo producto, procedimiento e intermediarios de preparación de derivados de azetidina